Ajanta Pharma Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

The inspection concluded with the issuance of a Form 483 containing five observations. The company said it will respond to the US FDA within the stipulated timeline.

A Form 483 indicates procedural or compliance deficiencies noted during inspection and does not constitute a warning letter or import action at this stage.

Ajanta Pharma is primarily involved in development, manufacturing and marketing of speciality pharmaceutical finished dosages.

The company?s consolidated net profit jumped 17.6% to Rs 273.77 crore on 20% rise in revenue from operations to Rs 1,374.84 crore in Q3 FY26 over Q3 FY25.

Shares of Ajanta Pharma fell 0.41% to Rs 2,784.40 on the BSE.

Ajanta Pharma announced that the USFDA has concluded an inspection at its manufacturing facility at Paithan, in Maharashtra. The Inspection was conducted from 13 April 2026, to 21 April 2026, and closed with the issuance of Form-483 with 5 (five) observations.

Ajanta Pharma will hold a meeting of the Board of Directors of the Company on 5 May 2026.

Ajanta Pharma Ltd is up for a third straight session in a row. The stock is quoting at Rs 2903.7, up 3.48% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.88% on the day, quoting at 23839.75. The Sensex is at 76813.27, down 0.95%. Ajanta Pharma Ltd has dropped around 1.71% in last one month.

Meanwhile, Nifty Pharma index of which Ajanta Pharma Ltd is a constituent, has dropped around 1.93% in last one month and is currently quoting at 22164.85, down 0.24% on the day. The volume in the stock stood at 74510 shares today, compared to the daily average of 1.05 lakh shares in last one month.

The PE of the stock is 37.14 based on TTM earnings ending December 25.